Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection
United States faces biggest burden of hepatitis C treatment costs before 2020
Coffee consumption linked to reduced liver fibrosis in people with HBV, HCV and NAFLD
High HCV cure rate demonstrated for people retreated after failure of short course direct-acting antiviral therapy
Triple DAA regimen cures hepatitis C patients with rapid response in just 3 weeks
Clinical impact of effective HCV DAAs: referrals for liver transplant drop after their introduction
Study reveals potential challenges for scaling up of HCV therapy in UK
Liver fibrosis improves after successful treatment for hepatitis C
Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice
Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C
Tenofovir during pregnancy reduces risk of mother-to-child hepatitis B virus transmission
New AbbVie hepatitis C combination cures 93 to 97% with genotype 3
Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients
Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation
Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment
Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows
New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study
